搜索医生

Julio C. Chavez, M.D., M.S.

  1. Internist
  2. Oncologist
预约门诊

出版物

  1. Baccon D, Zhou J, Atallah-Yunes SA, Wang JF, Hwang SR, Paludo J, Munoz JL, Iqbal M, Breen WG, Lester SC, Micallef IN, Abeykoon JP, Klebig RR, Rosenthal AC, Moustafa MA, Chavez JC, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS, Wang Y. Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis. Blood Neoplasia. 2026 Nov; 3 (4):100283 Epub 2026 Aug 11
    View PubMed
  2. Tao Y, Falade AS, Ogbue OD, Adeoye O, Khurana A, Johnston PB, Micallef IN, Durani U, Tiger YK, Abeykoon JP, Johnson A, Tsang M, Rosenthal AC, Hilal T, Munoz JL, Iqbal M, Moustafa MA, Chavez JC, Cerhan JR, Godby RC, Tun HW, Wang Y, Zhou J, Li H. Autologous haematopoietic stem cell transplant consolidation and survival outcomes in primary central nervous system lymphoma: Evidence from the National Cancer Database. Br J Haematol. 2026 Sep 30 Epub 2026 Sept 30
    View PubMed
  3. Faramand RG, Hammami MB, Bachmeier C, Chavez JC, Wang X, Shah B, Dam M, Lazaryan A, Mirza S, Gaballa S, Khimani F, Liu H, Nishihori T, Davila ML, Locke FL, Jain MD. Prophylaxis with Dexamethasone or Anakinra in Patients with High-Risk Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Transplant Cell Ther. 2026 Sep 27 Epub 2026 Sept 27
    View PubMed
  4. Hampel PJ, Huang Y, Allan JN, Bhat SA, Bond D, Brander DM, Byrd JC, Chavez JC, Chong E, Danilov A, Davids MS, Dvorak-Kornaus K, Freedman H, Malakhov N, Matasar M, Miller C, Miller S, Omer Z, Parikh SA, Parry EM, Rabe KG, Raess P, Rai M, Rhodes JM, Rogers KA, Saha A, Schade J, Shouse G, Spurgeon S, Stephens D, Wang Y, Woyach JA, Yano M, Kittai AS. Hodgkin lymphoma transformation in patients with chemotherapy-naive chronic lymphocytic leukemia. Blood Cancer J 2026 Sep 26; 16 (1) Epub 2026 Sept 26
    View PubMed
  5. Wang J, Yi D, Gao Y, Yang F, Klebig RR, Paludo J, Munoz JL, Moustafa MA, Iqbal M, Chavez JC, Wang Y, Abeykoon JP. Rituximab maintenance following frontline bendamustine-rituximab in mantle cell lymphoma: a systematic review and meta-analysis. Haematologica. 2026 Sep 24 Epub 2026 Sept 24
    View PubMed
  6. Castillo JJ, Beltran BE, Florindez JA, Chavez JC, Malpica L. Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management. Am J Hematol. 2026 Aug; 101 (8):1997-2006 Epub 2026 May 15
    View PubMed
  7. Alarcon Tomas A, Segura A, Chavez J. Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy. Expert Rev Hematol. 2026 Aug; 19 (8):881-892 Epub 2026 June 10
    View PubMed
  8. Parker NH, Kim J, Bean M, De Vera MT, Carmella R, Duca A, Corallo S, Delgado LC, Merritt E, McCoy J, Brushwood A, Franca M, Hansen DK, Castaneda Puglianini O, Lazaryan A, Chavez J, Nishihori T, Shah B, Faramand R, Mirza AS, Akhtar O, Peres LC, Figura NB, Jhaveri K, Oswald LB, Jim HSL, Locke FL, Jain M, Freeman CL. Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes. Transplant Cell Ther. 2026 Jun 18 Epub 2026 June 18
    View PubMed
  9. Saha A, Jhaveri K, Perini GF, Chavez JC. From immunomodulators (IMiDs) to cereblon E3 ligase modulator (CELMoDs): the evolution of cereblon modulators in lymphoma therapy. Leuk Lymphoma. 2026 Jun; 67 (7):1479-1491 Epub 2026 May 19
    View PubMed
  10. Iqbal M, Kumar A, Dreger P, Chavez J, Sauter CS, Sureda AM, Bachanova V, Maziarz RT, Dreyling M, Smith SM, Jacobson C, Glass B, Casulo C, Oluwole OO, Montoto S, Advani R, Cohen J, Salles G, Hamad N, Kuruvilla J, Kahl BS, Shadman M, Kanate AS, Budde LE, Kamdar M, Flowers C, Hamadani M, Kharfan-Dabaja MA. Corrigendum to 'Clinical Practice Recommendations for Hematopoietic Cell Transplantation.' Transplant Cell Ther. 2024 Sep;30(9):832-843. Transplant Cell Ther. 2026 Jun; 32 (6):760-761 Epub 2025 July 04
    View PubMed
  11. Jhaveri K, Chavez JC. Building on CD19 based therapy for relapse or refractory follicular lymphoma. Med. 2026 May 8; 7 (5):101101
    View PubMed
  12. Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin I, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu S, Wagner-Johnston N, Ollila TA, Grover N, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov A, Tun H, Munoz J, Narkhede M, Rhodes JM, Prica A, Kuhnl A, Maraj A, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Baidoun F, Monick SE, Trutzer IM, Can J, Ayers A, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K. Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma. Blood. 2026 Apr 16; 147 (16):1814-1827
    View PubMed
  13. Kharfan-Dabaja MA, Reljic T, Abdel-Razeq S, Sarhan Z, Mohty R, Keller K, Iqbal M, Chavez JC, Luo Y, Qin H, Aljurf M, Kumar A. Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma. Curr Res Transl Med. 2026 Apr-Jun; 74 (2):103590 Epub 2026 May 11
    View PubMed
  14. Miller CR, Huang Y, Allan JN, Bhat SA, Bond D, Brander D, Byrd JC, Chavez J, Chong E, Danilov A, Dowling MR, Dvorak-Kornaus K, Hampel PJ, Ho C, Islam P, Malakhov N, Matasar M, Miller S, Parikh SA, Rabe KG, Rhodes JM, Roeker LE, Rogers KA, Saha A, Skarbnik A, Scott H, Schade J, Shadman M, Shouse G, Sojitra P, Stephens DM, Thompson MC, Thompson PA, Wang Y, Woyach JA, Yano M, Omer Z, Kittai AS. Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era. Am J Hematol 2025 Sep; 100 (9):1709-1713 Epub 2025 July 02
    View PubMed
  15. Kittai AS, Huang Y, Miller S, Allan JN, Bhat SA, Bond DA, Brander DM, Byrd JC, Chavez JC, Chong E, Davids MS, Danilov AV, Ding W, Dowling MR, Dvorak-Kornaus K, Freedman H, Hampel PJ, Ho C, Hwang SR, Islam P, Malakhov N, Matasar M, Miller C, Omer Z, Parikh SA, Parry E, Rabe KG, Raess PW, Rai M, Roeker L, Rhodes J, Rogers KA, Saha A, Schade J, Scott HW, Shadman M, Shouse G, Skarbnik A, Spurgeon S, Stephens DM, Thompson MC, Thompson PA, Wang Y, Yano M, Woyach JA. Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J 2025 Feb 20; 15 (1):23
    View PubMed
  16. Jhaveri K, Saha A, Salcedo LM, Chavez JC. Bispecific antibody combination regimens for b-cell non-Hodgkin's lymphomas. Expert Opinion on Biological Therapy. 2025; 25 (11):1223-32
  17. Hoogland AI, Barata A, Li X, Irizarry-Arroyo N, Jain MD, Welniak T, Rodriguez Y, Oswald LB, Gudenkauf LM, Chavez JC, Khimani F, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Crowder SL, Parker NH, Carson TL, Vinci CE, Pidala JA, Logue J, Locke FL, Jim HSL. Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy. Transplant Cell Ther. 2024 Dec; 30 (12):1219.e1-1219.e11 Epub 2024 Sept 19
    View PubMed
  18. Stanchina MD, Montoya S, Danilov AV, Castillo JJ, Alencar AJ, Chavez JC, Cheah CY, Chiattone C, Wang Y, Thompson M, Ghia P, Taylor J, Alderuccio JP. Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887. Epub 2024 Nov 01.
    View PubMed
  19. Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, Barta SK, Caimi PF, Sethi TK, Reddy N, Karmali R, Bello C, Chavez JC, Kothari SK, Hernandez-Ilizaliturri FJ, Svoboda J, Lansigan F, Glenn MJ, Cohen JB, Sorge C, Christian B, Herrera AF, Hamadani M, Costa LJ, Xavier AC. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Adv. 2024 Nov 12; 8(21):5458-5466.
    View PubMed
  20. Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024 Oct 20; 42 (30):3581-3592 Epub 2024 Aug 02
    View PubMed
  21. Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol. 2024 Oct; 99 (10):2002-2015 Epub 2024 July 03
    View PubMed
  22. Saha A, Chavez JC. Recent developments in CD19-targeted therapies for follicular lymphoma. Expert Opin Biol Ther. 2024 Oct; 24 (10):1049-1055 Epub 2024 Sept 18
    View PubMed
  23. Castaneda Puglianini O, Chavez JC. CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies. Semin Hematol. 2024 Oct; 61 (5):290-296 Epub 2024 Aug 24
    View PubMed
  24. Kucharik AH, Curkovic NB, Chavez JC, Tsai KY, Brohl AS, Grichnik JM. Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton's tyrosine kinase inhibitor. JAAD Case Rep. 2024 Sep; 51:17-21 Epub 2024 July 01
    View PubMed
  25. Iqbal M, Kumar A, Dreger P, Chavez J, Sauter CS, Sureda AM, Bachanova V, Maziarz RT, Dreyling M, Smith SM, Jacobson C, Glass B, Casulo C, Oluwole OO, Montoto S, Advani R, Cohen J, Salles G, Hamad N, Kuruvilla J, Kahl BS, Shadman M, Kanate AS, Budde LE, Kamdar M, Flowers C, Hamadani M, Kharfan-Dabaja MA. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2024 Sep; 30 (9):832-843 Epub 2024 July 06
    View PubMed
  26. Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, Shah BD, Chavez J, Bello C, Lazaryan A, Khimani F, Ibarz JP, Liu HD, Locke FL, Jain MD, Zhang L, Kharfan-Dabaja MA, Kim J, Ayala E, Nishihori T, Sokol L. Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma. Transplant Cell Ther. 2024 Sep; 30(9):887.e1-887.e9. Epub 2024 May 11.
    View PubMed
  27. Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 Jul 09; 8(13):3507-3518.
    View PubMed
  28. Fowler NH, Chavez JC, Riedell PA. Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review. Target Oncol. 2024 Jul; 19 (4):495-510 Epub 2024 June 19
    View PubMed
  29. Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol. 2024 Jun 10; 42 (17):2071-2079 Epub 2024 Mar 29
    View PubMed
  30. Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, Shah BD, Lazaryan A, Chavez J, Khimani F, Pinilla-Ibarz JA, Dam M, Reid KM, Corallo SA, Menges M, Hidalgo Vargas M, Mandula JK, Holliday BA, Bachmeier CA, Speth K, Song Q, Mattie M, Locke FL, Davila ML. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma. Blood Cancer Discov. 2024 Mar 1; 5 (2):106-113
    View PubMed
  31. Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos D, Neelapu SS, Locke FL, Ghobadi A. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb 27; 8(4):1042-1050.
    View PubMed
  32. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024 Feb 8; 143 (6):496-506
    View PubMed
  33. Dong N, Zhang H, Song J, Mammadova J, Shah B, Saeed H, Gaballa S, Grajales-Cruz A, Isenalumhe L, Bello C, Sokol L, Pinilla J, Chavez J. B-cell maturation antigen expression and clinical features of plasmablastic lymphoma. EJHaem. 2024 Feb; 5 (1):285-289 Epub 2024 Jan 18
    View PubMed
  34. El Warrak S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, Chavez J, Mohty R. Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy. Bone Marrow Transplant. 2024 Feb; 59(2):162-170. Epub 2023 Dec 16.
    View PubMed
  35. Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan FT, Dholaria BR, Maakaron JE, Sandoval-Sus JD, Mishra R, Saha A, Annunzio K, Bhaskar ST, Sumransub N, Fijalka A, Ivanov SA, Lin Y, Kharfan-Dabaja MA. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2024 Feb; 59(2):211-216. Epub 2023 Nov 16.
    View PubMed
  36. Logothetis CN, Horvat NP, Kurian T, Bello C, Chavez J, Isenalumhe L, Shah B, Sokol L, Saeed H, Pinilla J, Gaballa S. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience. Oncol Res. 2024; 32 (6):1031-1036 Epub 2024 May 23
    View PubMed
  37. Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw LY, Jing J, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Chavez JC. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. Nat Med. 2024 Jan; 30(1):229-239. Epub 2023 Dec 10.
    View PubMed
  38. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang M, Cohen JB, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast M, Fenske T, Rao Gari SN, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Adv. 2023 Dec 26; 7(24):7393-7401.
    View PubMed
  39. Dong N, Perez-Lamas L, Chavez JC. Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma. Expert Opin Emerg Drugs. 2023 Dec; 28 (3):181-190 Epub 2023 Aug 30
    View PubMed
  40. Zhao Y, Amorrortu RP, Stewart SC, Ghia KM, Williams VL, Sondak VK, Tsai KY, Pinilla-Ibarz J, Chavez JC, Rollison DE. Melanoma and CLL co-occurrence and survival: role of KC history. BMC Cancer. 2023 Nov 9; 23 (1):1084 Epub 2023 Nov 09
    View PubMed
  41. Ibrahim U, Bassil C, Chavez JC, Khimani F, Jain MD, Locke FL, Osman K, Lazaryan A. CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease. Clin Lymphoma Myeloma Leuk. 2023 Oct; 23 (10):772-778 Epub 2023 May 12
    View PubMed
  42. Azem A, Caddell R, Nelson R, Isenalumhe L, Gaballa S, Chavez J, Bello C, Pinilla J, Sokol L, Shah B, Saeed H. Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population. Clin Lymphoma Myeloma Leuk. 2023 Aug; 23 (8):606-609 Epub 2023 Apr 24
    View PubMed
  43. Amorrortu RP, Zhao Y, Stewart S, Ghia KM, Williams VL, Sondak VK, Tsai KY, Pinilla J, Chavez J, Rollison DE. History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience. J Cancer Res Clin Oncol. 2023 Jul; 149 (7):3607-3621 Epub 2022 Aug 13
    View PubMed
  44. Saha A, Jhaveri K, Sarfraz H, Chavez JC. Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma. Expert Opin Biol Ther. 2023 Jul-Dec; 23 (9):869-876 Epub 2023 Aug 20
    View PubMed
  45. Dong N, Rubio Lopes-Garcia L, Vinal D, Bachmeier C, Shah BD, Nishihori T, Khimani F, Davila ML, Lazaryan A, Pinilla-Ibarz J, Locke FL, Jain MD, Chavez JC. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplant Cell Ther. 2023 Jun; 29 (6):349.e1-349.e8 Epub 2023 Mar 05
    View PubMed
  46. Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma. Clin Cancer Res. 2023 May 15; 29 (10):1869-1878
    View PubMed
  47. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023 May 11; 141(19):2307-2315.
    View PubMed
  48. Lee D, Jordan AI, Menges MA, Lazaryan A, Nishihori T, Gaballa SR, Shah BD, Pinilla-Ibarz J, Baluch A, Klinkova OV, Chavez JC, Jain MD, Locke FL. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. Transplant Cell Ther. 2023 Apr; 29 (4):277.e1-277.e9 Epub 2022 Aug 12
    View PubMed
  49. Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, Shah B, Lazaryan A, Khimani F, Nishihori T, Bachmeier C, Faramand R, Fradley MG, Jeong D, Oliveira GH, Locke FL, Davila ML, Alomar M. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023 Apr 1; 9 (1):18 Epub 2023 Apr 01
    View PubMed
  50. Hess BT, Giri A, Park Y, Patel KK, Link BK, Nowakowski GS, Maliske SM, Fortin S, Chavez JC, Saeed H, Hill BT, Mejia Garcia AV, Maddocks KJ, Hanel W, Wagner-Johnston ND, Messmer MR, Kahl BS, Watkins M, Alderuccio JP, Lossos IS, Nathan S, Orellana-Noia VM, Portell CA, Landsburg DJ, Ayers EC, Castillo JJ. Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. Am J Hematol. 2023 Feb; 98(2):300-308. Epub 2023 Jan 01.
    View PubMed
  51. Mohty R, Moreno Vanegas Y, Chavez JC, Kharfan-Dabaja MA. Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma. Expert Rev Anticancer Ther. 2023 Feb; 23(2):121-126. Epub 2023 Jan 24.
    View PubMed
  52. Mohty R, Kharfan-Dabaja MA, Chavez JC. Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes. Cancer Manag Res. 2023; 15:367-375 Epub 2023 Apr 19
    View PubMed
  53. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 Jan 01; 108(1):98-109.
    View PubMed
  54. Figura NB, Sim AJ, Jain MD, Chavez JC, Robinson TJ. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. Expert Rev Hematol. 2022 Dec; 15 (12):1023-1030 Epub 2022 Nov 17
    View PubMed
  55. Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 Dec; 28 (12):829.e1-829.e8 Epub 2022 Sept 26
    View PubMed
  56. Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, Dorritie K, Jaglowski S, Radford J, Morschhauser F, Cunningham D, Martin Garcia-Sancho A, Tzachanis D, Ulrickson ML, Karmali R, Kekre N, Thieblemont C, Enblad G, Dreger P, Malladi R, Joshi N, Wang WJ, Solem CT, Snider JT, Cheng P, To C, Kersten MJ. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood. 2022 Nov 24; 140 (21):2248-2260
    View PubMed
  57. Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 (10):753-759 Epub 2022 May 23
    View PubMed
  58. Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier CA, Chavez JC, Shah BD, Khimani F, Nishihori T, Lazaryan A, Davila ML, Mhaskar R, Locke FL, Gaballa S, Jain MD. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Adv. 2022 Jul 12; 6 (13):3970-3973
    View PubMed
  59. Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022 Jul; 97 (7):951-965 Epub 2022 May 03
    View PubMed
  60. Barata A, Hoogland AI, Kommalapati A, Logue J, Welniak T, Hyland KA, Eisel SL, Small BJ, Jayani RV, Booth-Jones M, Oswald LB, Gonzalez BD, Kirtane KS, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Transplant Cell Ther. 2022 Jul; 28 (7):401.e1-401.e7 Epub 2022 May 14
    View PubMed
  61. Gamarra Samaniego MDP, Blanquicett CJ, Araujo Castillo RV, Chavez JC, Beltran Garate BE. Selected Domains within a Comprehensive Geriatric Assessment in Older Patients with Non-Hodgkin Lymphoma are Highly Associated with Frailty. Clin Hematol Int. 2022 Jun; 4 (1-2):35-43 Epub 2022 May 11
    View PubMed
  62. Hoogland AI, Barata A, Logue J, Kommalapati A, Hyland KA, Nelson AM, Eisel SL, Small BJ, James BW, Christy SM, Bulls HW, Booth-Jones M, Jayani RV, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2022 Jun; 28 (6):305.e1-305.e9 Epub 2022 Apr 01
    View PubMed
  63. Nastoupil LJ, Kuruvilla J, Chavez JC, Bijou F, Witzig TE, Santoro A, Flinn IW, Boccomini C, Kenkre VP, Corradini P, Isufi I, Andorsky DJ, Klein LM, Greenwald DR, Sangha R, Shen F, Hagner P, Li Y, Dobmeyer J, Gong N, Uttamsingh S, Pourdehnad M, Ribrag V. Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. EJHaem. 2022 May; 3(2):394-405. Epub 2022 Feb 14.
    View PubMed
  64. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May; 9(5):e327-e339. Epub 2022 Apr 01.
    View PubMed
  65. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022 Apr; 28(4):735-742. Epub 2022 Mar 21.
    View PubMed
  66. Lee DH, Hawk F, Seok K, Gliksman M, Emole J, Rhea IB, Viganego F, Welter-Frost A, Armanious M, Shah B, Chavez JC, Pinilla-Ibarz J, Schabath MB, Fradley M. Association between ibrutinib treatment and hypertension. Heart. 2022 Mar; 108 (6):445-450 Epub 2021 July 01
    View PubMed
  67. Martin P, Bartlett NL, Chavez JC, Reagan JL, Smith SM, LaCasce AS, Jones J, Drew J, Wu C, Mulvey E, Revuelta MV, Cerchietti L, Leonard JP. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. 2022 Feb 24; 139 (8):1147-1159
    View PubMed
  68. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 Feb 17; 386(7):640-654. Epub 2021 Dec 11.
    View PubMed
  69. Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, Gandhi AK, Shen F, Michelliza S, Haeske H, Hege K, Pourdehnad M, Kuruvilla J. Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. EJHaem. 2022 Feb; 3 (1):139-153 Epub 2022 Jan 14
    View PubMed
  70. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Perez-Simon JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 Feb; 28 (2):325-332 Epub 2021 Dec 17
    View PubMed
  71. Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 Jan 20; 139 (3):413-423
    View PubMed
  72. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022 Jan; 23(1):91-103. Epub 2021 Dec 08.
    View PubMed
  73. Albanyan O, Chavez J, Munoz J. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma. Ther Adv Hematol. 2022; 13:20406207221141511. Epub 2022 Dec 06.
    View PubMed
  74. Davids MS, O'Connor OA, Jurczak W, Samaniego F, Fenske TS, Zinzani PL, Patel MR, Ghosh N, Cheson BD, Derenzini E, Brander DM, Reeves JA, Knopinska-Posluszny W, Allan JN, Phillips T, Caimi PF, Lech-Maranda E, Burke JM, Agajanian R, Pettengell R, Leslie LA, Cheah CY, Fonseca G, Essell J, Chavez JC, Pagel JM, Sharman JP, Hsu Y, Miskin HP, Sportelli P, Weiss MS, Flinn IW. Integrated safety analysis of umbralisib, a dual PI3Kdelta/CK1epsilon inhibitor, in relapsed/refractory lymphoid malignancies. Blood Adv. 2021 Dec 14; 5 (23):5332-5343
    View PubMed
  75. Figura NB, Robinson TJ, Sim AJ, Wang X, Cao B, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu HD, Kim S, Locke FL, Jain MD. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. Int J Radiat Oncol Biol Phys. 2021 Dec 01; 111(5):1145-1154. Epub 2021 Jul 06.
    View PubMed
  76. Logue JM, Chavez JC. How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure. Curr Treat Options Oncol. 2021 Oct 26; 22 (12):112
    View PubMed
  77. Cortes-Bullich A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, Nishihori T, Khimani F, Lazaryan A, Davila ML, Locke FL, Jain MD. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplant Cell Ther. 2021 Sep; 27 (9):768.e1-768.e6 Epub 2021 May 30
    View PubMed
  78. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 Sep; 35(9):2672-2683. Epub 2021 Mar 03.
    View PubMed
  79. Chavez JC, Yassine F, Sandoval-Sus J, Kharfan-Dabaja MA. Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. Int J Hematol Oncol. 2021 Jun; 10(2):IJH33. Epub 2021 Aug 03.
    View PubMed
  80. Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopinska-Posluszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Umbralisib, a Dual PI3Kdelta/CK1epsilon Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 May 20; 39 (15):1609-1618 Epub 2021 Mar 08
    View PubMed
  81. Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier C, Dean EA, Cao B, Chavez JC, Shah B, Lazaryan A, Nishihori T, Hussaini M, Gonzalez RJ, Mullinax JE, Rodriguez PC, Conejo-Garcia JR, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May 13; 137 (19):2621-2633
    View PubMed
  82. Yassine F, Sandoval-Sus J, Ayala E, Chavez J, Hamadani M, Kharfan-Dabaja MA. Cellular Therapies for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 May; 27(5):363-370. Epub 2021 Feb 06.
    View PubMed
  83. Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr 1; 106 (4):978-986 Epub 2021 Apr 01
    View PubMed
  84. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 Mar 23; 5(6):1648-1659.
    View PubMed
  85. Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, Booth-Jones M, Hyland KA, James BW, Barata A, Bachmeier CA, Chavez JC, Khimani F, Krivenko GS, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Abidi M, Locke FL, Jim HSL. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021 Mar; 10 (6):1936-1943 Epub 2021 Feb 28
    View PubMed
  86. Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar; 27 (3):242.e1-242.e6 Epub 2020 Dec 27
    View PubMed
  87. Aulakh S, Reljic T, Yassine F, Ayala E, Chavez JC, Chanan-Khan A, Pinilla-Ibarz J, Kumar A, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021 Mar; 14 (1):33-40 Epub 2020 May 15
    View PubMed
  88. Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, Chavez J, Pinilla-Ibartz J, Saeed H, Sandoval-Sus J, Isenalumhe L, Sokol L. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb; 21 (2):132-138 Epub 2020 Aug 27
    View PubMed
  89. Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. Drugs Context. 2021; 10 Epub 2021 Sept 21
    View PubMed
  90. Castaneda-Puglianini O, Chavez JC. Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma. J Blood Med. 2021; 12:775-783 Epub 2021 Aug 24
    View PubMed
  91. Sandoval-Sus J, Chavez JC. The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma. Ther Adv Hematol. 2021; 12:20406207211017788 Epub 2021 May 29
    View PubMed
  92. Yassine F, Iqbal M, Murthy H, Kharfan-Dabaja MA, Chavez JC. Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. Curr Res Transl Med. 2020 Nov; 68(4):159-170. Epub 2020 Aug 15.
    View PubMed
  93. Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 Oct; 191(1):44-51. Epub 2020 May 19.
    View PubMed
  94. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 Sep 20; 38 (27):3119-3128 Epub 2020 May 13
    View PubMed
  95. Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep 15; 26 (18):4823-4831 Epub 2020 July 15
    View PubMed
  96. Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep 08; 4(17):4086-4090.
    View PubMed
  97. Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, Balagurunathan Y, Locke FL. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 Jul 28; 4 (14):3268-3276
    View PubMed
  98. Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Oncologist. 2020 Jun; 25 (6):e993-e997 Epub 2020 Apr 28
    View PubMed
  99. Landsburg DJ, Ayers EC, Bond DA, Maddocks KJ, Karmali R, Behdad A, Curry M, Wagner-Johnston ND, Modi D, Ramchandren R, Assouline SE, Faramand R, Chavez JC, Torka P, Mier Hicks A, Medeiros LJ, Li S. Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. Br J Haematol. 2020 Apr; 189 (2):313-317 Epub 2019 Dec 05
    View PubMed
  100. Chavez JC, Jain MD, Kharfan-Dabaja MA. Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. Hematol Oncol Stem Cell Ther. 2020 Mar; 13(1):1-6. Epub 2019 Jun 10.
    View PubMed
  101. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Feb; 18 (2):185-217
    View PubMed
  102. Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 Jan 15; 126 (2):293-303 Epub 2019 Sept 30
    View PubMed
  103. Yang G, Mills M, Kim Y, Figura NB, Doyle C, Oliver D, Grass GD, Robinson T, Chavez J, Kim S. Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation. Blood Cancer J. 2020 Jan 02; 9(12):104.
    View PubMed
  104. Yang G, Mills M, Kim Y, Figura NB, Doyle C, Oliver D, Grass GD, Robinson T, Chavez J, Kim S. Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation. Blood Cancer J 2020 Jan 2; 9 (12):104 Epub 2020 Jan 02
    View PubMed
  105. Fradley MG, Welter-Frost A, Gliksman M, Emole J, Viganego F, Lee DH, Shah B, Chavez JC, Pinilla-Ibarz J, Schabath MB. Electrocardiographic Changes Associated With Ibrutinib Exposure. Cancer Control. 2020 Jan-Dec; 27 (1):1073274820931808
    View PubMed
  106. Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2020 Jan 1; 26 (1):54-60 Epub 2019 Oct 21
    View PubMed
  107. Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, Hassan MZO, Bassily E, Rhea I, Ismail-Khan R, Mulligan CP, Banerji D, Lazaryan A, Shah BD, Rokicki A, Raje N, Chavez JC, Abramson J, Locke FL, Neilan TG. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019 Dec 24; 74 (25):3099-3108
    View PubMed
  108. Sim AJ, Jain MD, Figura NB, Chavez JC, Shah BD, Khimani F, Lazaryan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim S, Locke FL, Robinson TJ. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019 Dec 01; 105(5):1012-1021. Epub 2019 Jun 05.
    View PubMed
  109. Mirza AS, Dholaria BR, Hussaini M, Mushtaq S, Horna P, Ravindran A, Kumar A, Ayala E, Kharfan-Dabaja MA, Bello C, Chavez JC, Sokol L. High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 Sep; 19(9):e513-e520. Epub 2019 Mar 29.
    View PubMed
  110. Fradley MG, Gliksman M, Emole J, Viganego F, Rhea I, Welter-Frost A, Armanious M, Lee DH, Walko C, Shah B, Chavez JC, McLeod H, Pinilla-Ibarz J, Schabath MB. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. Am J Cardiol. 2019 Aug 15; 124 (4):539-544 Epub 2019 May 25
    View PubMed
  111. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019 Jun 01; 17(6):650-661.
    View PubMed
  112. Grass GD, Mills MN, Ahmed KA, Liveringhouse CL, Montejo ME, Robinson TJ, Chavez JC, Harrison LB, Kim S. Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations. Leuk Lymphoma. 2019 Apr; 60(4):886-893. Epub 2018 Nov 20.
    View PubMed
  113. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leuk Lymphoma. 2019 Apr; 60(4):940-946. Epub 2018 Oct 02.
    View PubMed
  114. Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, Appelbaum J, Maloney DG. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 2019 Mar; 12 (3):195-205 Epub 2019 Mar 18
    View PubMed
  115. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J Clin Oncol. 2019 Feb 20; 37(6):471-480. Epub 2019 Jan 07.
    View PubMed
  116. Sandoval-Sus JD, Faramand R, Chavez J, Puri S, Parra P, Sokol L, Kharfan-Dabaja MA, Shah B, Ayala E. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. Leuk Lymphoma. 2019 Feb; 60(2):309-316. Epub 2018 Jul 02.
    View PubMed
  117. Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 Jan 24; 133(4):299-305. Epub 2018 Dec 06.
    View PubMed
  118. Phuoc V, Sandoval-Sus J, Chavez JC. Drug therapy for double-hit lymphoma. Drugs Context. 2019; 8 Epub 2019 Dec 02
    View PubMed
  119. Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019; 10:2040620719841581. Epub 2019 Apr 15.
    View PubMed
  120. Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine Release Syndrome: Current Perspectives. Immunotargets Ther. 2019; 8:43-52 Epub 2019 Oct 29
    View PubMed
  121. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan; 20(1):31-42. Epub 2018 Dec 02.
    View PubMed
  122. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw. 2019 Jan; 17(1):12-20.
    View PubMed
  123. Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham LV, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018 Dec 03; 128(12):5517-5530. Epub 2018 Nov 05.
    View PubMed
  124. Ayala E, Chavez JC, Gomez A, Sleiman E, Kumar A, Kharfan-Dabaja MA. Feasibility and Efficacy of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for HIV-Associated Lymphoma: A Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2018 Aug; 18(8):548-551. Epub 2018 May 23.
    View PubMed
  125. Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 Jul; 93 (7):953-962
    View PubMed
  126. Chavez JC, Locke FL. CAR T cell therapy for B-cell lymphomas. Best Pract Res Clin Haematol. 2018 Jun; 31 (2):135-146 Epub 2018 Apr 11
    View PubMed
  127. Hampras SS, Locke FL, Chavez JC, Patel NS, Giuliano AR, Miller K, Gheit T, Tommasino M, Rollison DE. Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma. 2018 Apr; 59 (4):911-917 Epub 2017 July 06
    View PubMed
  128. Dholaria BR, Ayala E, Sokol L, Nishihori T, Chavez JC, Hussaini M, Kumar A, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. Leuk Res. 2018 Apr; 67:1-5. Epub 2018 Jan 31.
    View PubMed
  129. Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, Fenske TS, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi PF, Hamadani M, Forman SJ, Hussaini M, de Lima M, Olteanu H, Shah B, Chavez JC, Al Malki M, Kumar A, Ganguly S. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Transplant. 2018 Mar; 24(3):486-493. Epub 2017 Dec 07.
    View PubMed
  130. Kharfan-Dabaja MA, Sheets K, Kumar A, Murthy HS, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez LE, Betts BC, Anasetti C, Pidala J. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. Br J Haematol. 2018 Mar; 180(6):854-862. Epub 2018 Jan 18.
    View PubMed
  131. Beltran BE, Quinones P, Morales D, Malaga JM, Chavez JC, Sotomayor EM, Castillo JJ. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2018 Feb; 36 (1):93-97 Epub 2017 June 22
    View PubMed
  132. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 Feb; 180(4):534-544. Epub 2017 Dec 19.
    View PubMed
  133. Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Transplant. 2018 Feb; 24(2):400-405. Epub 2017 Oct 13.
    View PubMed
  134. Juarez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. Cancer Control. 2018 Jan-Mar; 25 (1):1073274818778256
    View PubMed
  135. Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 Jan; 59(1):59-68. Epub 2017 Jun 22.
    View PubMed
  136. Jain MD, Bachmeier CA, Phuoc VH, Chavez JC. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. Ther Clin Risk Manag. 2018; 14:1007-1017 Epub 2018 May 31
    View PubMed
  137. Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan; 18(1):e35-e39. Epub 2017 Oct 12.
    View PubMed
  138. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28; 377(26):2531-2544. Epub 2017 Dec 10.
    View PubMed
  139. Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Dec; 15(12):1520-1541.
    View PubMed
  140. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Nov 15; 123(22):4411-4418. Epub 2017 Jul 27.
    View PubMed
  141. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1826-1838. Epub 2017 Aug 07.
    View PubMed
  142. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017 Jul 10; 35 (20):2260-2267 Epub 2017 May 05
    View PubMed
  143. Juarez-Salcedo LM, Sandoval-Sus J, Sokol L, Chavez JC, Dalia S. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now. Crit Rev Oncol Hematol. 2017 May; 113:52-62 Epub 2017 Mar 09
    View PubMed
  144. Abuodeh Y, Ahmed K, Echevarria M, Naghavi A, Grass GD, Robinson TJ, Tomblyn M, Shah B, Chavez J, Bello C, El-Haddad G, Harrison L, Kim S. Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. Ther Adv Hematol. 2017 Apr; 8(4):129-138. Epub 2017 Feb 01.
    View PubMed
  145. Ozoya OO, Chavez J, Sokol L, Dalia S. Optimizing antiviral agents for hepatitis B management in malignant lymphomas. Ann Transl Med. 2017 Feb; 5 (3):39
    View PubMed
  146. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. Am J Hematol. 2017 Feb; 92(2):161-170.
    View PubMed
  147. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017 Jan 4; 25 (1):285-295 Epub 2017 Jan 04
    View PubMed
  148. Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017 Jan; 19 (1):99-108 Epub 2016 Aug 30
    View PubMed
  149. Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Dec; 22(12):2201-2207. Epub 2016 Sep 19.
    View PubMed
  150. Juarez Salcedo LM, Sandoval-Sus J, Zhang L, Klippenstein D, Chavez JC. Excellent outcome of hairy cell leukaemia with extensive mesenteric infiltration following cladribine therapy. Br J Haematol. 2016 Sep; 174 (5):659 Epub 2016 July 08
    View PubMed
  151. Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug; 47:78-83. Epub 2016 May 17.
    View PubMed
  152. Chavez JC, Sandoval-Sus J, Horna P, Dalia S, Bello C, Chevernick P, Sotomayor EM, Sokol L, Shah B. Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2016 Aug; 16 Suppl:S170-4
    View PubMed
  153. Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016 May; 91 (5):529-37
    View PubMed
  154. Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, Fenske TS, Jaso J, Medeiros LJ, Yang DT, Nabhan C. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Cancer. 2016 Feb 15; 122 (4):559-64 Epub 2015 Nov 13
    View PubMed
  155. Beltran BE, Aguilar C, Quinones P, Morales D, Chavez JC, Sotomayor EM, Castillo JJ. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2016; 57 (1):58-62 Epub 2015 June 19
    View PubMed
  156. Sandoval-Sus JD, Chavez J, Dalia S. A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphoma Molecular Subtypes: A Cell of Origin-Driven Review. Curr Cancer Drug Targets. 2016; 16 (4):305-22
    View PubMed
  157. Roe C, Bennett J, Zhang L, Chavez J, Shah B, Sokol L, Komrokji R. Hemophagocytic Lymphohistiocytosis in Malignant Hematology: Uncommon but Should Not Be Forgotten? Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S147-50
    View PubMed
  158. Castillo JJ, Chavez JC, Hernandez-Ilizaliturri FJ, Montes-Moreno S. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol. 2015 Jun; 8 (3):343-54 Epub 2015 Feb 01
    View PubMed
  159. Chavez JC, Dalia S, Sandoval-Sus J, Kharfan-Dabaja MA, Al-Ali N, Komrokji R, Padron E, Corrales-Yepez G, Rock-Klotz J, Pinilla-Ibarz J. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S14-8.
    View PubMed
  160. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct 9; 124 (15):2354-61 Epub 2014 Aug 26
    View PubMed
  161. Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leuk Res. 2014 Oct; 38(10):1165-72. Epub 2014 Apr 28.
    View PubMed
  162. Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr; 99 (4):450-6 Epub 2014 Mar 01
    View PubMed
  163. Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013 Sep; 37 (9):1107-15 Epub 2013 June 26
    View PubMed
  164. Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013; 8:37-45 Epub 2013 May 16
    View PubMed
  165. Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):384-93. Epub 2010 Jul 22.
    View PubMed
  166. Kharfan-Dabaja MA, Chavez JC, Khorfan KA, Pinilla-Ibarz J. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer. 2008 Sep 01; 113(5):897-906.
    View PubMed
PST-20590287